CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Rapport Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Rapport Therapeutics Inc
1325 Boylston Street, Suite 401
Phone: (857) 321-8020p:857 321-8020 BOSTON, MA  02215  United States Ticker: RAPPRAPP
Business Summary
Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery and development of a portfolio of precision small molecule product candidates. The Company focuses on developing a new class of precision neuromedicines aimed at providing patients with alternatives to existing treatments for central nervous system disorders. It advances a pipeline of therapeutic programs to patients living with central nervous system (CNS) disorders, including focal onset epilepsy, pain, bipolar disorder, and hearing disorders. Its program ionotropic receptors for glutamate (iGluR) are ligand gated ion channels activated by the neurotransmitter glutamate. Its RAP-219 is a clinical-stage small molecule designed to achieve neuroanatomical specificity through its selective targeting of a RAP known as TARPy8, which is associated with the neuronal AMPAR, a clinically validated target for epilepsy.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Steven M.Paul 73 12/1/2022 12/1/2022
President, Chief Executive Officer, Director Abraham N.Ceesay 46 3/1/2023 2/28/2023
Chief Financial Officer Troy A.Ignelzi 56 11/1/2023 11/1/2023
10 additional Officers and Directors records available in full report.

Business Names
Business Name
RAPP
Rapport Therapeutics Securities Corporation

General Information
Number of Employees: 58 (As of 5/10/2024)
Outstanding Shares: 36,576,457 (As of 9/30/2024)
Stock Exchange: NASD
Federal Tax Id: 880724208
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, November 22, 2024